logo
  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

Facial Injectable Market, By Type (Collagen, Hyaluronic Acid, Botulinum toxin type A, polymers fillers, calcium hydroxylapatite), By Application (Therapeutic, Aesthetic) opportunities and forecast 2020-2027

  • DLR2226
  • 20 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

The cosmetic industry is booming in the current decade and has experienced over projected three-fold increase in the turnover in the last few decades. There has been a rise in total number of the non-surgical therapies, including injections of dermal fillers and wrinkle relaxers. The trend is primarily due to various technological advancements, such as less risk of infections, low recovery time, no blood loss, and overall reduction in the procedural costs. Thus, the rise in the number of these procedures has encouraged the growth of overall industry including facial injectable.

Additionally, factors like, rising awareness about the external appearance among old and young individuals and growing awareness regarding availability of numerous products and procedures, accredited to the social media influence and increasing globalization are likely to further fuel the growth of the market.

Segment Overview

On the basis of type, the facial injectable market is segmented into collagen, botulinum toxin type A, calcium hydroxylapatite, hyaluronic acid, and polymer fillers. The hyaluronic acid segment ruled the market in 2019 and is anticipated to witness productive growth during the forecast period. Increasing use of hyaluronic acid in the cosmetic industry is likely to support the market growth. Hyaluronic acid has become an essential part of the cosmetics owing to strong water holding properties and minor allergic reactions. Cosmetic-grade products has a low molecular weight which facilitates deep penetration of product in the epidermis, releases antioxidants, helps retain water in the cells, and delays aging process, hence contributing towards the market demand.

Regional Overview

North America held major market share in 2019, owing to the increased spending on various aesthetic procedures and easy accessibility of the products. In addition, existence of large geriatric population base in the U.S. and Canada is further likely to fuel demand for these injectables during the forecast period. As per the estimates provided by United States Census Bureau (USCB) in 2014, the geriatric population in the country is likely to reach 83.7 million by the year 2050 from 43.1 million in 2012.

Europe is also estimated to hold considerable market share during the forecast period owing to the increasing disposable income coupled with presence of highly innovative healthcare infrastructure and manufacturers. This is likely to assist the market growth for facial injectable over the forecast period. Furthermore, local presence of major players including ALLERGAN, Sinclair Pharma, Ipsen, and Galderma S.A. are likely to assist in growth of this vertical.

Competitor overview

Some of the key players include ALLERGAN; Merz Pharma; Suneva, Ipsen; Medical, Inc.; Prollenium Medical Technologies Inc.; Medytox, Inc.; Bloomage BioTechnology Corporation Limited; Sinclair Pharma; Anika Therautics, Inc.; and Galderma S.A. The players focusing on growth strategies, such as partnerships, new product launches, regional expansions mergers and acquisitions. For instance, in Jan 2017, ALLERGAN introduced Juvéderm Volite, a hyaluronic acid based injectable gel used to smoothen the face lines, décolletage, neck, and hands in adults.

Key Players
  1. ALLERGAN;
  2. Ipsen;
  3. Merz Pharma;
  4. Suneva Medical, Inc.;
  5. Medytox, Inc.;
  6. Sinclair Pharma;
  7. Bloomage BioTechnology Corporation Limited;
  8. Anika Therapeutics, Inc.;
  9. Prollenium Medical Technologies Inc.;
  10. Galderma S.A.

Market Segmentation

By Type
  • Collagen
  • Hyaluronic Acid
  • Botulinum Toxin Type A
  • Calcium Hydroxylapatite
  • Polymer Fillers
By Application
  • Aesthetics
  • Therapeutic
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 MARKET OVERVIEW 12

  • 1.1 PRODUCT OVERVIEW AND SCOPE OF FACIAL INJECTABLE 12
  • 1.2 SPECIFICATIONS OF FACIAL INJECTABLE 13
    • 1.2.1 HYALURONIC ACID 13
    • 1.2.2 COLLAGEN 13
    • 1.2.3 BOTULINUM TOXIN 13
    • 1.2.4 POLYMERS AND PARTICLES 14

2 RESEARCH METHODOLGY 17

  • 2.1 PRIMARY RESEARCH: 18
  • 2.2 SECONDARY RESEARCH: 18

3 MARKET DYNAMICS 19

  • 3.1 DRIVERS 19
    • 3.1.1 GROWING DEMAND FOR FACIAL AESTHETIC TREATMENTS 19
    • 3.1.2 TECHNOLOGICAL ADVANCEMENTS 19
    • 3.1.3 EFFECTS OF POLLUTION 19
    • 3.1.4 INCREASING ACCEPTANCE OF SOFT TISSUE FILLERS 20
    • 3.1.5 GROWING DEMAND FOR DERMAL FILLER TECHNIQUES FROM ASIAN REGION 20
  • 3.2 RESTRAINTS: 20
    • 3.2.1 COMPLICATION DURING SURGERY 20
    • 3.2.2 SIDE EFFECTS ASSOCIATED WITH FACIAL INJECTABLE 21
  • 3.3 OPPORTUNITY 21
    • 3.3.1 RISING AWARENESS ABOUT COMBINATION THERAPIES 21
  • 3.4 PORTERS FIVE FORCES 22
  • 3.5 BARGAINING POWER OF SUPPLIERS 23
  • 3.6 BARGAINING POWER OF BUYERS 23
  • 3.7 THREAT OF NEW ENTRANTS 23
  • 3.8 THREAT OF SUBSTITUTES 23
  • 3.9 INTENSITY OF RIVALRY 23
  • 3.10 VALUE CHAIN ANALYSIS 24
    • 3.10.1 INPUTS 24
    • 3.10.2 DRUG DEVELOPMENT 24
    • 3.10.3 MANUFACTURING PROCESS OF FACIAL INJECTABLE 24
    • 3.10.4 MARKETING AND DISTRIBUTION 25
  • 3.11 SUPPLY CHAIN 25

4 GLOBAL FACIAL INJECTABLE MARKET BY REGIONS 27

  • 4.1 GLOBAL FACIAL INJECTABLE MARKET 27
  • 4.2 NORTH AMERICA FACIAL INJECTABLE MARKET 29
  • 4.3 NORTH AMERICA FACIAL INJECTABLE MARKET, BY TYPE 32
  • 4.4 NORTH AMERICA FACIAL INJECTABLE MARKET, BY APPLICATION 35
  • 4.5 NORTH AMERICA FACIAL INJECTABLE MARKET, BY COUNTRY: PRICE ($) 36
    • 4.5.1 BOTULINUM TOXIN PRICE: BY COUNTRY ($) 36
    • 4.5.2 HYALURONIC ACID PRICE: BY COUNTRY ($) 36
    • 4.5.3 POLYMERS AND PARTICLES PRICE: BY COUNTRY ($) 37
    • 4.5.4 COLLAGEN PRICE: BY COUNTRY ($) 37
  • 4.6 NORTH AMERICA NUBER OF FACIAL INJECTABLE PROCEDURES BY COUNTRY, 2013-2021 38
    • 4.6.1 BOTULINUM TOXIN 38
    • 4.6.2 HYALURONIC ACID 38
    • 4.6.3 POLYMERS & PARTICLES 38
    • 4.6.4 COLLAGEN 39
  • 4.7 US FACIAL INJECTABLE MARKET 40
    • 4.7.1 U.S FACIAL INJECTABLE MARKET BY TYPE 40
    • 4.7.2 U.S FACIAL INJECTABLE MARKET BY APPLICATIONU.S. FACIAL INJECTABLE MARKET, BY APPLICATION (USD MILLION) 41
    • 4.7.3 U.S FACIAL INJECTABLE MARKET BYTYPE: PRICE ($) 42
  • 4.8 CANADA FACIAL INJECTABLE MARKET 42
    • 4.8.1 CANADA FACIAL INJECTABLE MARKET BY TYPE 42
    • 4.8.2 CANADA FACIAL INJECTABLE MARKET BY APPLICATION 44
    • 4.8.3 CANADA FACIAL INJECTABLE MARKET BY TYPE: PRICE ($) 45
  • 4.9 EUROPE FACIAL INJECTABLE MARKET 45
    • 4.9.1 EUROPE FACIAL INJECTABLE MARKET, BY TYPE 45
    • 4.9.2 EUROPE FACIAL INJECTABLE MARKET, BY APPLICATION 48
    • 4.9.3 EUROPE FACIAL INJECTABLE MARKET, BY TYPE: PRICE ($) 50
  • 4.10 EUROPE FACIAL INJECTABLE MARKET, BY COUNTRY (USD MILLION) 50
    • 4.10.1 RUSSIA FACIAL INJECTABLE MARKET 50
    • 4.10.2 GERMANY FACIAL INJECTABLE MARKET 51
    • 4.10.3 FRANCE FACIAL INJECTABLE MARKET 51
    • 4.10.4 U.K. FACIAL INJECTABLE MARKET 52
    • 4.10.5 ITALY FACIAL INJECTABLE MARKET 52
    • 4.10.6 SPAIN FACIAL INJECTABLE MARKET 53
    • 4.10.7 REST OF EUROPE FACIAL INJECTABLE MARKET 53
  • 4.11 EUROPE FACIAL INJECTABLE MARKET TYPES BY COUNTRY (VOLUME) 54
    • 4.11.1 EUROPE HYALURONIC ACID 54
    • 4.11.2 EUROPE BOTULINUM TOXIN 54
  • 4.12 EUROPE FACIAL INJECTABLE MARKET BY APPLICATION (USD MILLION) 55
    • 4.12.1 RUSSIA FACIAL INJECTABLE MARKET 55
    • 4.12.2 GERMANY FACIAL INJECTABLE MARKET 55
    • 4.12.3 FRANCE FACIAL INJECTABLE MARKET 55
    • 4.12.4 U.K. FACIAL INJECTABLE MARKET 56
    • 4.12.5 ITALY FACIAL INJECTABLE MARKET 56
    • 4.12.6 SPAIN FACIAL INJECTABLE MARKET 56
    • 4.12.7 REST OF EUROPE FACIAL INJECTABLE MARKET 57
  • 4.13 ASIA FACIAL INJECTABLE MARKET 57
  • 4.14 ASIA FACIAL INJECTABLE MARKET, BY TYPE 60
    • 4.14.1 ASIA BOTULINUM TOXIN MARKET, BY COUNTRY 60
    • 4.14.2 ASIA HYALURONIC ACID MARKET, BY COUNTRY 61
    • 4.14.3 ASIA POLYMERS & PARTICLES MARKET, BY COUNTRY 62
    • 4.14.4 ASIA COLLAGEN MARKET, BY COUNTRY 63
  • 4.15 ASIA FACIAL INJECTABLE MARKET, BY APPLICATION 63
  • 4.16 ASIA FACIAL INJECTABLE MARKET,BY TYPE: PRICE ($) 65
  • 4.17 ASIA FACIAL INJECTABLE PROCEDURE: BY COUNTRY 66
    • 4.17.1 SOUTH KOREA FACIAL INJECTABLE MARKET 68
    • 4.17.2 JAPAN FACIAL INJECTABLE MARKET 69
    • 4.17.3 CHINA FACIAL INJECTABLE MARKET 71
    • 4.17.4 INDIA FACIAL INJECTABLE MARKET 72
    • 4.17.5 REST OF ASIA FACIAL INJECTABLE MARKET 73

5 COMPETITIVE LANDSCAPE 75

  • 5.1 GLOBAL FACIAL INJECTABLE MARKET COMPETITION BY MANUFACTURERS 75
    • 5.1.1 GLOBAL FACIAL INJECTABLE SALES AND MARKET SHARE OF KEY MANUFACTURERS (2015 AND 2016) 75
  • 5.2 GLOBAL FACIAL INJECTABLE MARKET: COMPANY SHARE ANALYSIS, 2015 (%) 76

6 GLOBAL FACIAL INJECTABLE MARKET: COMPANY PROFILE 77

  • 6.1 GALDERMA 77
    • 6.1.1 COMPANY OVERVIEW 78
    • 6.1.2 PRODUCT OVERVIEW 78
    • 6.1.3 FINANCIALOVERVIEW 78
    • 6.1.4 MANUFACTURING UNITS. 79
  • 6.2 ALLERGAN 81
    • 6.2.1 COMPANY OVERVIEW 81
    • 6.2.2 PRODUCT OVERVIEW 82
    • 6.2.4 KEY DEVELOPMENTS 83
  • 6.3 MERZ PHARMA 84
    • 6.3.1 COMPANY OVERVIEW 85
    • 6.3.2 PRODUCT OVERVIEW 85
    • 6.3.3 FINANCIAL OVERVIEW 86
    • 6.3.4 KEY DEVLOPMENTS 87
    • 6.3.5 MANUFACTURING UNITS 87
  • 6.4 VALEANT PHARMACEUTICALS 88
    • 6.4.1 COMPANY OVERVIEW 89
    • 6.4.2 PRODUCT OVERVIEW 89
    • 6.4.3 FINANCIAL OVERVIEW 90
    • 6.4.4 KEY DEVELOPMENTS 90
    • 6.4.5 MANUFACTURING UNITS 91
  • 6.5 INTEGRA LIFESCIENCES 94
    • 6.5.1 COMPANY OVERVIEW 94
    • 6.5.2 PRODUCT OVERVIEW 94
    • 6.5.4 KEY DEVELOPMENTS 95
    • 6.5.5 MANUFACTURING UNITS 96
  • 6.6 SANOFI 97
    • 6.6.1 COMPANY OVERVIEW 97
    • 6.6.2 PRODUCT OVERVIEW 97
    • 6.6.3 FINANCIAL OVERVIEW 98
    • 6.6.4 KEY DEVELOPMENTS 98
  • 6.7 SINCLAIR 99
    • 6.7.1 COMPANY OVERVIEW 99
    • 6.7.2 PRODUCT OVERVIEW 99
    • 6.7.3 FINANCIAL OVERVIEW: 100
    • 6.7.4 KEY DEVELOPMENTS 100
  • 6.8 SUNEVA MEDICAL 101
    • 6.8.1 COMPANY OVERVIEW 101
    • 6.8.2 PRODUCT OVERVIEW 101
    • 6.8.3 FINANCIAL OVERVIEW 101
  • 6.9 SCIVISION BIOTECH INC. 102
    • 6.9.1 COMPANY OVERVIEW 102
    • 6.9.2 PRODUCT OVERVIEW 102
    • 6.9.3 FINANCIAL OVERVIEW 102

7 FACIAL INJECTABLE MARKET: TECHNOLOGY AND DEVELOPMENT TREND 103

    8 CONCLUSION 105

    Report You Might be Interested